Molbio Diagnostics IPO Allotment Status: Check on KFin Technologies, BSE & NSE

Molbio Diagnostics IPO allotment is scheduled for Thursday, August 13, 2026, after the IPO received a strong 70.26x subscription. QIB demand was particularly high at 186.389x. Investors can check their allotment status through KFin Technologies, BSE, or NSE.

If allotted, shares are scheduled to be credited to demat accounts on August 14, with the listing planned for August 17. This guide explains exactly how to check the status and what happens next.

Important Dates

• Allotment Date: Thursday, August 13, 2026
• Refund Initiation: Friday, August 14, 2026
• Demat Credit: Friday, August 14, 2026
• Listing Date: Monday, August 17, 2026

How to Check Molbio Diagnostics IPO Allotment Status?

Method 1: Check on BSE

Investors can check their allotment directly through the BSE website.

• Visit the BSE IPO allotment status page: https://www.bseindia.com/investors/appli_check
• Select Equity under the issue type.
• Select Molbio Diagnostics from the IPO list.
• Enter your application number or PAN details, as required.
• Complete the verification and submit to view your allotment status.

If your application number shows shares allotted, you should see the number of shares credited to your application.

Method 2: Check on NSE

You can also check the allotment status through NSE.

• Visit the NSE IPO status section: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids
• Select Molbio Diagnostics from the list.
• Enter your application details or PAN, depending on the available option.
• Complete the required verification.
• Submit the details to check your allotment.

Method 3: Check on the Registrar

KFin Technologies is the registrar for the Molbio Diagnostics IPO. The registrar maintains the application and allotment records.

• Visit the KFin Technologies IPO allotment status page: https://ipostatus.kfintech.com/
• Select Molbio Diagnostics.
• Choose the identification method, such as PAN or application number.
• Enter the required details.
• Submit the form to see whether shares have been allotted.

Molbio Diagnostics IPO Subscription Details

Source: INDmoney

• Institutional demand was the strongest: QIBs subscribed 186.389x, far above the retail subscription of 12.956x. This shows that institutional participation was particularly strong.
• Overall demand was extremely high: At 70.26x, the issue received applications for roughly 70 times the shares available. This also means the chances of receiving a full retail allotment are constrained by oversubscription.

The strong subscription is notable because Molbio is being valued at around ₹9,300 crore at the upper price band. Investors appear to have shown significant interest despite the company's dependence on government healthcare programmes and TB diagnostics.

What’s Next After Allotment?

If shares are allotted

• Your allotment status should become visible on the registrar, BSE, or NSE platform once the process is completed. Shares are scheduled to be credited to your demat account on August 14, 2026.
• Because the IPO was subscribed 70.26x overall, investors should not expect every application to receive a full allotment. In an oversubscribed retail category, shares are generally allotted according to the applicable allotment rules, which can mean some investors receive a smaller quantity while others receive no shares.
• The next major event is the planned August 17 listing. Investors can then decide whether to hold or sell based on the market price and their own investment strategy.

If shares are not allotted

• If you do not receive shares, the amount blocked for the IPO should be released through the applicable refund or UPI unblock process. The scheduled refund date is August 14, 2026.
• The high subscription means non-allotment is a normal possibility, particularly because demand was much higher than the number of shares available.
• Not getting an allotment does not mean you cannot own Molbio shares. Investors who remain interested can consider buying the stock after listing, but the market price may be different from the IPO price and could move significantly.

Final Word

The key takeaway is that Molbio Diagnostics IPO attracted exceptionally strong demand, led by QIBs at 186.389x, but heavy subscription does not by itself prove that the stock is attractively valued.

For investors who applied, the immediate step is simple: check the allotment on August 13 through KFin Technologies, BSE, or NSE, and watch for demat credit or UPI unblocking on August 14.

To prepare for listing day, read our guide on what to do after an IPO lists: sell, hold, or buy.

Read the RA disclaimer here.